QualiZeal Welcomes Healthcare Industry Visionary Dr. Aiman Abdel-Malek to Business Advisory Board
With more than 25 years in executive leadership roles at GE, Qualcomm, and Insulet Corporation, Dr. Abdel-Malek is a recognized expert in secure, connected diabetes management systems and mobile healthcare solutions. Under his distinguished leadership, Insulet launched the world's first FDA-cleared, smartphone-controlled tubeless insulin patch pump and artificial pancreas. With over 40 patents and publications in secure connected healthcare, digital care delivery, and safe AI, he serves as a board advisor to several companies driving personalized healthcare innovation through digital technology and AI.
"Welcoming Dr. Aiman Abdel-Malek to our Business Advisory Board is a tremendous honor," said Kalyan Konda, Co-Founder, Executive Director, and CEO of QualiZeal. "His proven track record in AI-driven healthcare breakthroughs will provide invaluable strategic guidance as we solidify our market leadership and advance toward our goal of quadrupling the company by 2028. Dr. Abdel-Malek's strategic counsel will be crucial in shaping our next generation of innovation, expanding our global impact, and solidifying our position as a leader in modern quality engineering."
Dr. Aiman Abdel-Malek shared his enthusiasm about the partnership, stating, 'I believe QualiZeal will redefine how Quality Engineering is being practiced. The highly innovative, patent-pending QMentisAI platform is truly a game-changer. It's the industry's most complete end-to-end GenAI-powered QE platform, dramatically accelerating the journey from functional requirements to automated testing with regulatory-grade precision, reducing process times by over 60%. Backed by visionary leadership and a world-class team, QualiZeal has the clarity, innovation, and momentum to lead the industry. I'm proud to join them on this exciting journey.'
About QualiZeal:
QualiZeal is the world's fastest-growing Quality Engineering (QE) services company, known for its automation-first, AI-led, and platform-driven approach to software quality. With a diverse portfolio of digital transformation services—including Quality Engineering, Digital Engineering, Advisory & Transformation, and Emerging Technology Testing—QualiZeal empowers leading global organizations to achieve quality excellence and sustainable market leadership. QualiZeal's award-winning proprietary platforms, QMentisAI (patent-pending) and QualiCentral, pioneer the innovative use of AI and GenAI to solve complex QE challenges at speed and scale for clients in their digital transformation journeys. Recognized by Gartner, Everest Group, Forrester, Frost & Sullivan, and NelsonHall, the company has received numerous accolades, including the 2025 Gold Stevie® Award for Fastest Growing Tech Company of the Year (American Business Awards®). Trusted by 70+ global enterprise clients and backed by 850+ elite quality engineers, QualiZeal drives seamless digital transformation—reflected in its industry-leading Net Promoter Score (NPS) of 75.
For more information, please visit https://qualizeal.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Politico
2 hours ago
- Politico
Senate passes first funding package ahead of shutdown cliff
'It's taken a great deal of work, good faith and negotiation to get to this point,' Senate Appropriations Chair Susan Collins (R-Maine). 'Congress has a responsibility, a constitutional responsibility under Article I, for the power of the purse. We are executing that responsibility.' The package would provide almost $154 billion for military construction and veterans programs. It would send more than $27 billion to the Agriculture department and FDA. Both represent a roughly 2 percent boost over current levels. The Senate rejected an amendment from Sen. Jeff Merkley, an appropriator and the top Democrat on the Senate Budget Committee, that would bar the rescission, or clawback, of funds in the bill by the White House. Democrats are worried that the administration will send another rescissions package ahead of the fall funding deadline, which would likely implode any hopes of getting a larger funding deal. Still, Sen. Patty Murray, the top Democrat on the Appropriations Committee, defended the smaller deal reached among senators, saying that the package 'rejects damaging cuts from Trump and House Republicans.' The Senate adopted by voice vote an amendment from Democratic Sens. Richard Blumenthal of Connecticut and Alex Padilla of California that would bar the use of any funds in the bill to reduce services provided by the Veterans Crisis Line. Senators rejected other amendments from Democrats including one that would have halted funding of the Agriculture Department reorganization and another to require a report on staffing reductions at the VA. They also rejected amendments from Sens. John Kennedy (R-La.) and Rick Scott (R-Fla.) that would have made deeper cuts to the Agriculture-FDA bill. The chamber also voted 75-21 to reject a proposal from Sen. Ron Johnson of Wisconsin that would bar lawmakers from taking credit for earmarks. It would require the funding to be revoked if a lawmaker were to ever tout their earmarks in interviews, mailings, speeches or even on the campaign trail.
Yahoo
4 hours ago
- Yahoo
Regeneron cancer bispecific rejected again; Allogene discloses trial death
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Regeneron Pharmaceuticals and Allogene Therapeutics, as well as updates from Bristol Myers Squibb, Biogen, and Argenx that you may have missed. Regeneron said two more of its new drugs hit regulatory setbacks because of Food and Drug Administration inspection issues at a third-party manufacturing plant. The company received a complete response letter for its bispecific cancer antibody odronextamab in lymphoma on July 30, due to issues at an Indiana factory that Novo Nordisk recently acquired from Catalent. In addition, the FDA will delay a decision on an application for high-dose Eylea processed at that plant. The odronextamab setback will require Regeneron to refile its application. The FDA previously rejected another Regeneron bispecific antibody, now approved as Lynozyfic, in multiple myeloma because of third-party manufacturing issues. — Jonathan Gardner Allogene Therapeutics is stopping use of an experimental immunosuppresive antibody called ALLO-647 following the death of a study participant, the company said Friday. ALLO-647 is part of a regimen meant to prepare patients for treatment with Allogene's donor-derived cell therapy for blood cancer, . But the antibody has been associated in rare cases with severe viral infections and, in this instance, was deemed related to an adenovirus infection that triggered liver failure in a participant in Allogene's pivotal trial. Allogene has closed the study arm with ALLO-647 and won't use it in future trials. It will move forward with a standard two-drug immunosuppressive regimen often used in cancer cell therapy. Results from the pivotal trial are still expected next year, the company said. — Ben Fidler Bristol Myers Squibb boosted its revenue outlook for 2025 by $700 million, driven by higher-than-expected sales of its off-patent cancer drug Revlimid. The company now expects full-year sales to be between $46.5 and $47.5 billion, although that may not flow through to the bottom line because of the $1.5 billion it has spent this year to license a BioNTech cancer drug. The unexpectedly high $838 million in Revlimid sales in the second quarter were part of a broader overperformance by the company, which beat Wall Street consensus for both its old and new drug business lines. Sales of Eliquis, Opdivo and Reblozyl were higher than expected, although cell therapy Abecma and new psoriasis drug Sotyktu were below, according to Leerink Partners analyst David Risinger. — Jonathan Gardner Biogen shares rose as much as 7% Thursday after the biotechnology company's latest earnings report surpassed Wall Street expectations. The company recorded $2.6 billion in revenue from April through the end of June, with $160 million coming from Leqembi, its closely watched drug for Alzheimer's disease. Biogen also raised its forecasts for 2025 revenue and earnings per share. To Brian Abrahams, an analyst at the investment bank RBC Capital Markets, the results were indicative that Biogen's efforts to turn around the business are starting to show. 'We see considerable room for upside,' he wrote in a note to clients. — Jacob Bell Shares of Argenx climbed by double digits following quarterly sales numbers for its autoimmune drug Vyvgart that handily topped investor expectations. According to Argenx, the company's multiple Vyvgart formulations combined to generate nearly $949 million in revenue between April and June, beating consensus estimates by more than $80 million. The 'blowout' performance included 'impressive' numbers across Vyvgart's approved indications and different versions, wrote William Blair analyst Myles Minter on Thursday. Leerink Partners' Thomas Smith now projects more than $9 billion in combined peak yearly sales. Argenx's market value rose past $40 billion on the news. — Ben Fidler Recommended Reading Eli Lilly's Julie Gilmore on finding up-and-coming companies and backing small biotechs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
